Cytokines in graft-versushost disease and graft-versusleukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 387

[206] Bocchietto E, Guglielmetti A, Silvagno F, Taraboletti G, Pescarmona GP, Mantovani A,
et al. Proliferative and migratory responses of murine microvascular endothelial cells to
granulocyte-colony-stimulating factor. J Cell Physiol 1993;155(1):89-95.
[207] Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/
CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced
by GCSF or cyclophosphamide. J Clin Invest 2003;111(2):187-96.
[208] MacDonald KP, Rowe V, Filippich C, Johnson D, Morris ES, Clouston AD, et al. Chronic
graft-versus-host disease after granulocyte colony-stimulating factor-mobilized al-
logeneic stem cell transplantation: the role of donor T-cell dose and differentiation. Biol
Blood Marrow Transplant 2004;10(6):373-85.
[209] Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of
acute and chronic graft-versus-host disease on relapse and survival after bone marrow
transplantation from HLA-identical siblings as treatment of acute and chronic leuke-
mia. Blood 1989;73(6):1720-8.
[210] MacDonald KP, Rowe V, Filippich C, Thomas R, Clouston AD, Welply JK, et al. Donor
pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating fac-
tor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
Blood 2003;101(5):2033-42.
[211] Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment
with granulocyte colony-stimulating factor after allogeneic bone marrow transplanta-
tion for acute leukemia increases the risk of graft-versus-host disease and death: a
study from the Acute Leukemia Working Party of the European Group for Blood and
Marrow Transplantation. J Clin Oncol 2004;22(3):416-23.
[212] Khoury HJ, Loberiza Jr FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY, et al. Impact of
posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell trans-
plantation. Blood 2006;107(4):1712-6.
[213] Morris ES, MacDonald KP, Kuns RD, Morris HM, Banovic T, Don AL, et al. Induction of
natural killer T cell-dependent alloreactivity by administration of granulocyte colony-
stimulating factor after bone marrow transplantation. Nat Med 2009;15(4):436-41.
[214] Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithy-
mocyte globulin and soluble TNF[alpha] inhibitor (etanercept) +/− mycophenolate
mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow
Transplant 2006;37(12):1143-7.
[215] Markey KA, MacDonald KPA, Hill GR. Impact of cytokine gene polymorphisms on graft-
vs-host disease. Tissue Antigens 2008;72(6):507-16.
[216] Sykes M, Pearson DA, Taylor PA, Szot GL, Goldman SJ, Blazar BR. Dose and timing of
interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-
host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow trans-
plant recipients. Biol Blood Marrow Transplant 1999;5(5):277-84.
[217] Kimura F, Sato K, Akiyama H, Sao H, Okamoto S, Kobayashi N, et al. M-CSF at-
tenuates severity of chronic GVHD after unrelated BMT. Bone Marrow Transplant
2012;47(3):426-9.

391